A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PART I We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform. This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases. Our masking strategy is designed to reduce binding of biologic therapeutics to their targets until the mask is removed by proteases in the tumor microenvironment, providing more selective targeting of the tumor and optimizing the predicted therapeutic index of our clinical candidates.
| Segment | 2019 | % of Total |
|---|---|---|
Bristol Myers Squibb | $18M | 100% |
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 76M | 76M | 138M | 101M | 53M | - |
| Net Income | -20M | -20M | 32M | -569K | -99M | -116M |
| EPS | $-0.15 | $-0.15 | $0.38 | $-0.01 | $-1.51 | $-1.81 |
| Free Cash Flow | -76M | -76M | -87M | -57M | -113M | -121M |
| ROIC | -19.5% | -41.3% | 20.6% | -1.9% | -38.8% | -129.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.04 | 0.04 | -20.58 | -0.29 | -0.21 | 0.20 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -22M | -22M | 25M | -6.5M | -101M | -116M |
| Operating Margin | -29.3% | -29.3% | 18.1% | -6.4% | -190.6% | - |
| ROE | -20.6% | -41.3% | - | - | - | -129.6% |
| Shares Outstanding | 136M | 136M | 170M | 57M | 66M | 64M |
CytomX Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
CytomX Therapeutics, Inc. trades at 10.3x trailing earnings, compared to its 15-year median P/E of 2.7x, suggesting it is currently Expensive relative to its historical range. At current prices, the estimated annualized return to fair value is -23.8%.
CytomX Therapeutics, Inc. (CTMX) has a current P/E ratio of 10.3, compared to its historical median P/E of 2.7. The stock is currently considered Expensive based on its historical valuation range.
CytomX Therapeutics, Inc. (CTMX) has a 5-year average return on invested capital (ROIC) of -38.2%. This is below average and may indicate limited pricing power.
CytomX Therapeutics, Inc. (CTMX) has a market capitalization of $617M. It is classified as a small-cap stock.
CytomX Therapeutics, Inc. (CTMX) does not currently pay a regular dividend.
Based on historical P/E analysis, CytomX Therapeutics, Inc. (CTMX) appears expensive. The current P/E of 10.3 is 281% above its historical median of 2.7. The estimated fair value CAGR (P/E method) is 87.1%.
CytomX Therapeutics, Inc. (CTMX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CytomX Therapeutics, Inc. (CTMX) reported annual revenue of $76 million in its most recent fiscal year, based on SEC EDGAR filings.
CytomX Therapeutics, Inc. (CTMX) has a net profit margin of -26.7%. The company is currently unprofitable.
CytomX Therapeutics, Inc. (CTMX) generated $-76 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CytomX Therapeutics, Inc. (CTMX) has a debt-to-equity ratio of 0.04. This indicates a conservatively financed balance sheet.
CytomX Therapeutics, Inc. (CTMX) reported earnings per share (EPS) of $-0.15 in its most recent fiscal year.
CytomX Therapeutics, Inc. (CTMX) has a return on equity (ROE) of -41.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 13 years of financial data for CytomX Therapeutics, Inc. (CTMX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CytomX Therapeutics, Inc. (CTMX) has a book value per share of $0.73, based on its most recent annual SEC filing.